NCT02817997 International Registry for Patients With Castleman Disease
| NCT ID | NCT02817997 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Castleman Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2016-10 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2016-10 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.
Eligibility Criteria
Inclusion Criteria: * Person of any age * Have a reference pathology report suggesting "Castleman disease" not limited to cutaneous involvement only that can be uploaded * Be able to provide electronic informed consent, as per local regulations * Deceased patients may also be enrolled when a reference pathology report suggesting "Castleman disease" can be supplied or when the ART is able to locate and upload such a pathology report. Exclusion Criteria: * Because this registry is designed to provide as wide a picture of routine clinical practice as possible, inclusion criteria are set deliberately wide and there are no exclusion criteria.
Contact & Investigator
Joshua Brandstadter, MD, PhD, MSc
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT02817997 clinical trial?
This trial is open to participants of all sexes, studying Castleman Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02817997 currently recruiting?
Yes, NCT02817997 is actively recruiting participants. Contact the research team at joshua.brandstadter@pennmedicine.upenn.edu for enrollment information.
Where is the NCT02817997 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT02817997 clinical trial?
NCT02817997 is sponsored by University of Pennsylvania. The principal investigator is Joshua Brandstadter, MD, PhD, MSc at University of Pennsylvania. The trial plans to enroll 1,000 participants.